Blueprint Medicines Corp Stock Total Debt
BPMC Stock | USD 90.61 3.76 4.33% |
Blueprint Medicines Corp fundamentals help investors to digest information that contributes to Blueprint Medicines' financial success or failures. It also enables traders to predict the movement of Blueprint Stock. The fundamental analysis module provides a way to measure Blueprint Medicines' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Blueprint Medicines stock.
The current year's Total Debt To Capitalization is expected to grow to 0.88. Blueprint | Total Debt |
Blueprint Medicines Corp Company Total Debt Analysis
Blueprint Medicines' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Blueprint Medicines Total Debt | 774.12 M |
Most of Blueprint Medicines' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Blueprint Medicines Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Blueprint Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Blueprint Medicines is extremely important. It helps to project a fair market value of Blueprint Stock properly, considering its historical fundamentals such as Total Debt. Since Blueprint Medicines' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Blueprint Medicines' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Blueprint Medicines' interrelated accounts and indicators.
Click cells to compare fundamentals
Blueprint Total Debt Historical Pattern
Today, most investors in Blueprint Medicines Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Blueprint Medicines' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Blueprint Medicines total debt as a starting point in their analysis.
Blueprint Medicines Total Debt |
Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Competition |
Blueprint Short Long Term Debt Total
Short Long Term Debt Total |
|
Based on the latest financial disclosure, Blueprint Medicines Corp has a Total Debt of 774.12 M. This is 71.86% lower than that of the Biotechnology sector and 138.35% higher than that of the Health Care industry. The total debt for all United States stocks is 85.44% higher than that of the company.
Blueprint Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Blueprint Medicines' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Blueprint Medicines could also be used in its relative valuation, which is a method of valuing Blueprint Medicines by comparing valuation metrics of similar companies.Blueprint Medicines is currently under evaluation in total debt category among related companies.
Blueprint Medicines Institutional Holders
Institutional Holdings refers to the ownership stake in Blueprint Medicines that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Blueprint Medicines' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Blueprint Medicines' value.Shares | Jpmorgan Chase & Co | 2023-12-31 | 1.5 M | Lord, Abbett & Co Llc | 2023-12-31 | 1.4 M | Alliancebernstein L.p. | 2023-12-31 | 1.4 M | Geode Capital Management, Llc | 2023-12-31 | 1.3 M | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 1.2 M | Goldman Sachs Group Inc | 2023-12-31 | 1.2 M | Polar Capital Holdings Plc | 2023-12-31 | 865 K | Woodline Partners Lp | 2023-12-31 | 814.5 K | American Century Companies Inc | 2023-12-31 | 711.7 K | Blackrock Inc | 2023-12-31 | 6.6 M | Vanguard Group Inc | 2023-12-31 | 6.1 M |
Blueprint Fundamentals
Return On Equity | -1.57 | ||||
Return On Asset | -0.25 | ||||
Profit Margin | (2.03) % | ||||
Operating Margin | (1.46) % | ||||
Current Valuation | 5.38 B | ||||
Shares Outstanding | 61.23 M | ||||
Shares Owned By Insiders | 0.85 % | ||||
Shares Owned By Institutions | 99.15 % | ||||
Number Of Shares Shorted | 4.37 M | ||||
Price To Earning | 7.93 X | ||||
Price To Book | 40.90 X | ||||
Price To Sales | 21.42 X | ||||
Revenue | 249.38 M | ||||
Gross Profit | 177.28 M | ||||
EBITDA | (474.61 M) | ||||
Net Income | (506.98 M) | ||||
Cash And Equivalents | 853.11 M | ||||
Cash Per Share | 14.28 X | ||||
Total Debt | 774.12 M | ||||
Debt To Equity | 0.14 % | ||||
Current Ratio | 6.00 X | ||||
Book Value Per Share | 2.14 X | ||||
Cash Flow From Operations | (436.85 M) | ||||
Short Ratio | 5.37 X | ||||
Earnings Per Share | (8.37) X | ||||
Target Price | 97.38 | ||||
Number Of Employees | 655 | ||||
Beta | 0.65 | ||||
Market Capitalization | 5.32 B | ||||
Total Asset | 1.05 B | ||||
Retained Earnings | (2.34 B) | ||||
Working Capital | 593.47 M | ||||
Current Asset | 170.42 M | ||||
Current Liabilities | 18.64 M | ||||
Net Asset | 1.05 B |
About Blueprint Medicines Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Blueprint Medicines Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Blueprint Medicines using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Blueprint Medicines Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Blueprint Medicines
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Blueprint Medicines position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Blueprint Medicines will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Blueprint Medicines could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Blueprint Medicines when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Blueprint Medicines - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Blueprint Medicines Corp to buy it.
The correlation of Blueprint Medicines is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Blueprint Medicines moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Blueprint Medicines Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Blueprint Medicines can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Blueprint Medicines Piotroski F Score and Blueprint Medicines Altman Z Score analysis. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Complementary Tools for Blueprint Stock analysis
When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |
Is Blueprint Medicines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.37) | Revenue Per Share 4.118 | Quarterly Revenue Growth 0.855 | Return On Assets (0.25) | Return On Equity (1.57) |
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.